EGFR-Mutated Advanced NSCLC: Enhancing Treatment Strategies and Patient Care With Novel Therapies
Optimizing Patient Care in EGFR-Mutated NSCLC: AE Management and Supportive Care Strategies
Real World Insights: Bispecific Antibodies in R/R MM
Optimizing Care Transitions in Multiple Myeloma: Bridging Academic and Community Practices for Bispecific Antibody Therapy
GPRC5D-Targeted Therapies in Relapsed Multiple Myeloma: Real-World Results and Community Practice Challenges
Treatment Sequencing Strategies in R/R Multiple Myeloma
Current and Emerging Bispecifics in Multiple Myeloma: Clinical Data Review
Optimal Strategies for Managing Adverse Events with GPRC5D Bispecifics in Multiple Myeloma
Optimizing Transition of Care in Multiple Myeloma: Bridging the Gap Between Academic and Community Settings
Optimal Strategies for Managing Adverse Events with CAR-T Therapy in Multiple Myeloma
CAR T-Cell Therapy in Multiple Myeloma: Clinical Data and Patient Selection
Navigating Adverse Events and Toxicities in NSCLC Therapy: Challenges and Strategies
Exploring Advancements in the Treatment of Non–Small Cell Lung Cancer with EGFR Alterations
Bispecifics in Multiple Myeloma: Payer Perspectives
Session 7: Institutional Perspectives from Mayo Clinic: Implementing Treatment with Bispecifics in Practice
Session 6: Insights from Health Care Systems on Bispecifics: Patient Treatment, Monitoring and Transition of Care
Session 5: Sequencing Therapies for Multiple Myeloma in the Era of Bispecific Antibodies
Session 4: Managing Dysgeusia, Neuropathy and Other Toxicities with Bispecific Antibodies in Multiple Myeloma
Session 3: Monitoring and Managing Infections in Patients with MM Treated with Bispecific Antibodies
Session 2: Step-up Dosing and Monitoring for CRS and ICANS in Multiple Myeloma Patients Treated with Bispecifics
Session 1: BCMA and Non-BCMA Targeting Bispecifics in Multiple Myeloma: Clinical Data
